Magle Chemoswed (MAGLE) Q2 2026 earnings summary

Executive summary

• Revenue for Q2 2026 increased to 74.6 MSEK from 55.2 MSEK year-over-year, with H1 revenue at 146.3 MSEK versus 140.3 MSEK last year.

• The group remains loss-making, with Q2 EBIT at -13.1 MSEK (improved from -29.0 MSEK) and net loss after tax at -17.0 MSEK (from -27.8 MSEK).

• Early signs of operational stabilization are noted, but financial position remains tight and dependent on recapitalization.

Financial highlights

• EBITDA for Q2 was 1.5 MSEK, up from -6.6 MSEK in Q1 and 20.6 MSEK in Q2 2025.

• H1 2026 EBITDA was -5.0 MSEK, down from -1.8 MSEK in H1 2025.

• Non-recurring costs of 16.1 MSEK in Q2 related to legal, advisory, and interim management fees.

• Cash and cash equivalents at June 30, 2026, were 2.1 MSEK, down from 13.6 MSEK at end of 2025.

Outlook and guidance

• Recapitalization is underway, including new secured financing, debt-to-equity conversion, and a directed share issue, pending shareholder approval.

• Voluntary delisting from Nasdaq First North Growth Market is planned, subject to approval.

• Substantial dilution for existing shareholders is expected if recapitalization completes.